7/29/2015 - 9:50 AM EST - RepliCel Life Sciences Inc. : Announced that the final design specifications of its next-generation dermal injector (RCI-02) have been locked. Prototypes for industrial and regulatory testing will now be built to prepare for an application for CE mark clearance to market the injector in Europe in 2016. RepliCel Life Sciences Inc.
shares V.RP are trading up $0.005 at $0.41.
